Anidulafungin 100 mg powder for concentrate for solution for infusion – patient leaflet, side effects, dosage

1. What Anidulafungin is and what it is used for

Anidulafungin 100 mg powder for concentrate for solution for infusion contains the active substance anidulafungin and is prescribed in adults and in paediatric patients aged 1 month to less than 18 years to treat a type of fungal infection of the blood or other internal organs called invasive candidiasis. The infection is caused by fungal cells (yeasts) called Candida. Anidulafungin belongs to a group of medicines called echinocandins. These medicines are used to treat serious fungal infections.

Anidulafungin prevents normal development of fungal cell walls. In the presence of Anidulafungin, fungal cells have incomplete or defective cell walls, making them fragile or unable to grow.

2. What you need to know before you use Anidulafungin

Do not use Anidulafungin

• if you are allergic to anidulafungin, other echinocandins (e.g.caspofungin acetate), or

  any of the other ingredients of this medicine (listed in section 6). Warnings and precautions

Talk to your doctor or pharmacist or nurse before using Anidulafungin. Your doctor may decide to monitor you

• for liver function more closely if you develop liver problems during your treatment.

• if you are given anaesthetics during your treatment with Anidulafungin for signs of an

  allergic reaction such as itching, wheezing, blotchy skin

• for signs of an infusion–related reaction which could include a rash, hives, itching,

  redness,

• for shortness of breath/breathing difficulties, dizziness or lightheadedness Children and adolescents

Anidulafungin should not be given to patients under 1 month of age.

Other medicines and Anidulafungin

Tell your doctor or pharmacist if you or your child are taking, have recently taken or might take any other medicines.

Pregnancy and breast-feeding

The effect of Anidulafungin in pregnant women is not known. Therefore Anidulafungin is not recommended during pregnancy. Effective contraception should be used in women of childbearing age. Contact your doctor immediately if you become pregnant while taking Anidulafungin.

The effect of Anidulafungin in breast-feeding women is not known. Ask your doctor or pharmacist for advice before taking Anidulafungin while breast-feeding. Ask your doctor or pharmacist for advice before taking any medicines.

Anidulafungin contains fructose

This medicine contains 100 mg fructose (a type of sugar) in each vial.

If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.

If you (or your child) have hereditary fructose intolerance (HFI), a rare genetic disorder, you (or your child) must not receive this medicine. Patients with HFI cannot break down fructose in this medicine, which may cause serious side effects.

You must tell your doctor before receiving this medicine if you (or your child) have HFI or if your child can no longer take sweet foods or drinks because they feel sick, vomit or get unpleasant effects such as bloating, stomach cramps or diarrhoea.

Sodium content

This medicinal product contains less than 1 mmol sodium (23 mg) per vial, that is to say essentially ‘sodium free’

Anidulafungin contains Polysorbate 80

This medicine contains 250 mg of polysorbate 80 in each 100 mg vial dose, which is equivalent to 1.92 mg/mL of polysorbate 80 in the solution that will be infused into you or your child.

Polysorbates may cause allergic reactions. Tell your doctor if you or your child have any known allergies.

Polysorbates can have an effect on your heart and blood circulation (e.g. irregular or abnormal heartbeat, or low blood pressure).

3. How to use Anidulafungin

Anidulafungin will always be prepared and given to you or your child by a doctor or a healthcare professional (there is more information about the method of preparation at the end of the leaflet in the section for medical and healthcare professionals only). For use in adults, the treatment starts with 200 mg on the first day (loading dose). This will be followed by a daily dose of 100 mg (maintenance dose).

For use in children and adolescents (age from 1 month to less than 18 years), the treatment starts with 3.0 mg/kg (not to exceed 200 mg) on the first day (loading dose). This will be followed by a daily dose of 1.5 mg/kg (not to exceed 100 mg) (maintenance dose). The dose that is given depends on the patient’s weight.

Anidulafungin should be given to you once a day, by slow infusion (a drip) into your vein. For adults, this will take at least 1.5 hours for the maintenance dose and 3 hours for the loading dose. For children and adolescents, the infusion may take less time depending on the patient’s weight.

Your doctor will determine the duration of your treatment and how much Anidulafungin you will receive each day and will monitor your response and condition.

In general, your treatment should continue for at least 14 days after the last day Candida was found in your blood.

If you receive more Anidulafungin than you should

If you are concerned that you may have been given too much Anidulafungin, tell your doctor or another healthcare professional immediately.

If you forgot to use Anidulafungin

As you will be given this medicine under close medical supervision, it is unlikely that a dose would be missed. However tell your doctor or pharmacist if you think that a dose has been forgotten.

You should not be given a double dose by the doctor to make up for the forgotten dose. If you stop using Anidulafungin

You should not experience any effects from Anidulafungin if your doctor stops Anidulafungin treatment.

Your doctor may prescribe another medicine following your treatment with Anidulafungin to continue treating your fungal infection or prevent it from returning.

If your original symptoms come back, tell your doctor or another healthcare professional immediately.

If you have any further questions on the use of this medicine, ask your doctor, or pharmacist or nurse.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them. Some of these side effects will be noted by your doctor while monitoring your response and condition.

Life-threatening allergic reactions that might include difficulty breathing with wheezing or worsening of an existing rash have been rarely reported during administration of Anidulafungin.

Serious side effects – tell your doctor or another healthcare professional immediately should any of the following occur:

• Convulsion (seizure)
• Flushing
• Rash, pruritus (itching)
• Hot flush
• Hives
• Sudden contraction of the muscles around the airways resulting in wheezing or coughing
• Difficulty of breathing

Other side effects

Very common side effects (may affect more than 1 in 10 people) are:

• Low blood potassium (hypokalaemia)
• Diarrhoea
• Nausea

Package leaflet: Information for the user

Anidulafungin 100 mg powder for concentrate for

solution for infusion

Anidulafungin

Common side effects (may affect up to 1 in 10 people) are:

• Convulsion (seizure)
• Headache
• Vomiting
• Changes in blood tests of liver function
• Rash, pruritus (itching)
• Changes in blood tests of kidney function
• Abnormal flow of bile from the gallbladder into the intestine (cholestasis)
• High blood sugar
• High blood pressure
• Low blood pressure

• Sudden contraction of the muscles around the airways resulting in wheezing or

  coughing

• Difficulty of breathing

Uncommon side effects (may affect up to 1 in 100 people) are:

• Disorder of blood clotting system
• Flushing
• Hot flush
• Stomach pain
• Hives
• Pain at injection site

Not known (frequency cannot be estimated from the available data) are:

• Life-threatening allergic reactions

Reporting of side effects

If you get any side effects, talk to your doctor or, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Anidulafungin

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the label. The expiry data refers to the last day of that month.

Store in a refrigerator (2ºC – 8ºC).

The reconstituted solution may be stored up to 25ºC for up to 24 hours. The infusion solution may be stored at 25°C (room temperature) for 48 hours or stored frozen for at least 72 hours and should be administered at 25ºC (room temperature) within 48 hours. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Anidulafungin contains

• The active substance is anidulafungin. Each vial of powder contains 100 mg

  anidulafungin.

• The other ingredients are: fructose (see section 2 “Anidulafungin contains fructose”),

  mannitol, polysorbate 80 (see section 2 “Anidulafungin contains Polysorbate 80”), tartaric acid, sodium hydroxide (for pH-adjustment) (see section 2 “Anidulafungin contains sodium”), hydrochloric acid (for pH-adjustment)

What Anidulafungin looks like and contents of the pack

Anidulafungin is supplied as a box containing 1 or 5 vials of 100 mg powder for concentrate for solution for infusion.

Not all pack sizes may be marketed

The powder is white to off-white.

Marketing Authorisation Holder

Reig Jofre UK Limited

Follaton House, Plymouth Road,

Totnes, Devon, TQ9 5NE, UK

Manufacturer

Laboratorio Reig Jofré, S.A.

C/ Gran Capitán, 10

08970 Sant Joan Despí (Barcelona)

Spain

This leaflet was last revised in 06/2026.

Other sources of information

Detailed information on this medicine is available on the website of United Kingdom/MHRA

----------------------------------------------------------------------------------------The following information is intended for medical or healthcare professionals only and applies only to the single vial Anidulafungin 100 mg powder for concentrate for solution for infusion presentation:

The contents of the vial must be reconstituted with water for injections and subsequently diluted with ONLY 9 mg/mL (0.9%) sodium chloride for infusion or 50 mg/mL (5%) glucose for infusion. The compatibility of reconstituted Anidulafungin with intravenous substances, additives, or medicines other than 9 mg/mL (0.9%) sodium chloride for infusion or 50 mg/ mL (5%) glucose for infusion has not been established.

Reconstitution

Aseptically reconstitute each vial with 30 mL water for injection to provide a concentration of 3.33 mg/ mL. The reconstitution time can be up to 5 minutes. After subsequent dilution, the solution is to be discarded if particulate matter or discoloration is identified. The reconstituted solution is a clear colourless solution.

The reconstituted solution may be stored up to 25°C for up to 24 hours prior to further dilution. Dilution and infusion

Parenteral medicinal products should be inspected visually for particulate matter and discolouration prior to administration, whenever solution and container permit. If either particulate matter or discolouration is identified, discard the solution.

Adult Patients

Aseptically transfer the contents of the reconstituted vial(s) into an intravenous bag (or bottle) containing either 9 mg/mL (0.9%) sodium chloride for infusion or 50 mg/mL (5%) glucose for infusion to obtain the appropriate anidulafungin concentration. The table below provides the dilution to a concentration of 0.77 mg/mL for the final infusion solution and infusion instructions for each dose.

Dilution requirements for Anidulafungin administration

^A Either 9 mg/mL (0.9%) sodium chloride for infusion or 50 mg/mL (5%) glucose for infusion. ^B Infusion solution concentration is 0.77 mg/mL

The rate of infusion should not exceed 1.1 mg/min equivalent to 1.4 mL/min or 84 mL/hour when reconstituted and diluted per instructions.

Paediatric Patients

For paediatric patients aged 1 month to < 18 years, the volume of infusion solution required to deliver the dose will vary depending on the weight of the patient. The reconstituted solution must be further diluted to a concentration of 0.77 mg/mL for the final infusion solution. A programmable syringe or infusion pump is recommended. The rate of infusion should not exceed 1.1 mg/minute (equivalent to 1.4 mL/minute or 84 mL/hour when reconstituted and diluted per instructions).

1. 1. Calculate patient dose and reconstitute vial(s) required according to reconstitution instructions to provide a concentration of 3.33 mg/mL
2. 2. Calculate the volume (mL) of reconstituted anidulafungin required: Volume of anidulafungin (mL) = Dose of anidulafungin (mg) ÷ 3.33 mg/mL
3. 3.

   Calculate the total volume of dosing solution (mL) required to provide a final concentration of 0.77 mg/mL:

   Total volume of dosing solution (mL) = Dose of anidulafungin (mg) ÷ 0.77 mg/mL

4. 4. Calculate the volume of diluent [5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP (normal saline)] required to prepare the dosing solution: Volume of diluent (mL) = Total volume of dosing solution (mL) – Volume of anidulafungin (mL)
5. 5. Aseptically transfer the required volumes (mL) of anidulafungin and 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP (normal saline) into an infusion syringe or IV infusion bag needed for administration.

For single use only. Waste materials should be disposed of in accordance with local requirements.

B1XXXX-06